| NATIONAL HEALTH RESEARCH INSTITUTES Patent applications |
| Patent application number | Title | Published |
|---|
| 20120130053 | SOLID PHASE GOLD NANOPARTICLE SYNTHESIS - A method of synthesizing ligand-conjugated gold nanoparticles (AuNPs) is disclosed. The method comprises: a) providing an amine-modified silica particle; b) providing a solution comprising Au | 05-24-2012 |
| 20120123302 | Multiple-Frequency Ultrasonic Phased Array Driving System - An apparatus for sonicating a patient includes an ultrasound array having a plurality of transducers; a driving module for driving said transducers; and a control kernel for causing said driving module to drive said transducers concurrently at two different frequencies. | 05-17-2012 |
| 20120122154 | METHOD OF PRODUCING LIPIDATED POLYPEPTIDES - A method of producing a recombinant lipidated polypeptide in | 05-17-2012 |
| 20120121628 | LIPIDATED POLYEPITOPE VACCINES - This invention relates to, inter alia, an isolated lipidated polypeptide including a lipid moiety at the N-terminus and a plurality of epitopes, and methods of making and using the polypeptide. | 05-17-2012 |
| 20120046238 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION - A method for treating an infection with a virus. The method includes administering to a subject in need thereof an effective amount of one or more coumarin compounds of formula (I): | 02-23-2012 |
| 20120045468 | Immunogenic Compositions and Uses Thereof - Disclosed are methods of producing a purified EV71 virus antigen. Also disclosed are related immunogenic compositions and immunization methods. | 02-23-2012 |
| 20120041179 | Preparation and Purification of Subunit Vaccine for Neisseria Meningitidis (NM) Group B Isolates - A method for preparing and purifying recombinant lipoprotein Ag473 of | 02-16-2012 |
| 20110275643 | AROYLQUINOLINE COMPOUNDS - A serious of nitro heterocyclic derivatives including a structure of formula (I) are provided. In formula (I), P, Q and R1 to R8 are defined in the specification. The derivatives disclosed in the present invention are characterized in inhibiting tubulin polymerization, and treating cancers and other tubulin polymerization-related disorders with a suitable pharmaceutical acceptable carrier. | 11-10-2011 |
| 20110263620 | QUINOLINE COMPOUNDS AND THEIR USE FOR TREATING VIRAL INFECTION - Quinoline compounds of formula (I): | 10-27-2011 |
| 20110251137 | GAMMA-POLYGLUTAMIC ACID-BASED OCULAR IRRIGATING SOLUTIONS - Ophthalmic irrigating solutions are disclosed. The ophthalmic irrigating solution comprises: a) γ-polyglutamic acid (γ-PGA) and/or salt thereof in an amount effective to increase the viscosity of the irrigating solution; and b) an ophthalmically acceptable aqueous vehicle for the γ-PGA and/or salt thereof. Also disclosed is a method of irrigating ocular tissues of a patient, in which the method comprises introducing to the ocular tissues of the patient an ophthalmic irrigating solution comprising γ-PGA) and/or salt thereof in an amount sufficient to irrigate the ocular tissues of the patient. | 10-13-2011 |
| 20110229904 | RECOMBINANT CONSTRUCT FOR DETECTION OF HALOGENATED AROMATIC HYDROCARBONS - The present invention describes a recombinant construct for detection of halogenated aromatic hydrocarbon compounds. A method for detecting halogenated aromatic hydrocarbon compounds using the recombinant construct is also described. | 09-22-2011 |
| 20110200676 | CROSS-LINKED OXIDATED HYALURONIC ACID FOR USE AS A VITREOUS SUBSTITUTE - A composition comprising a polymer that comprises oxidated hyaluronic acid cross-linked by a dihydrazide is disclosed. The polymer is a hydrogel exhibiting the following properties: a) transparent and colorless; and b) transforming from a liquid state into a gel-matrix at 37° C. These characteristics make it useful as a vitreous humor substitute. | 08-18-2011 |
| 20110185440 | CISD2-Knockout Mice and Uses Thereof - The present invention is related to a Cisd2 knockout mouse with phenotype comprising mitochondrial breakdown and dysfunction, wherein Cisd2 is defined as SEQ ID NO. 1. The present invention is also related to a mouse model of Wolfram Syndrome 2 (WFS2) disease consisting of a Cisd2 knockout mouse. The present invention is further related to a method for screening a candidate agent for preventing or treating WFS2 disease. | 07-28-2011 |
| 20110172261 | DIBENZO[f,h]ISOQUINOLINE DERIVATIVES - A group of novel dibenzo[f,h]isoquinoline derivatives as shown in the specification. Also disclosed are methods of using the compounds for treating a disease associated with NO overproduction, cancer, or viral infection. | 07-14-2011 |
| 20110166437 | RECEIVING SURFACE COILS USED DURING THERMAL ABLATION PROCEDURE - A magnetic resonance imaging system to be used over a target area of a subject includes first and second RF coils for receiving an RF signal from the subject. The first RF coil is fixed to a position device and movable over the target area of subject. The second RF coil is larger than the first RF coil and has a larger field of view than the first RF coil. The system further includes an image processing device programmed to process RF signals coupled from the first RF coil and the second RF coil to form an MRI image. | 07-07-2011 |
| 20110166141 | CATHEPSIN S INHIBITORS - Cathepsin S inhibitors having formula (I), (II), (III) or (IV) as shown in the specification. These inhibitors can be used to treat cancer and autoimmune/inflammatory diseases. | 07-07-2011 |
| 20110136799 | PROLINE DERIVATIVES - Compounds of formula (I): | 06-09-2011 |
| 20110126297 | TRANSGENIC ANIMAL WITH MONOCYTE CHEMOTACTIC PROTEIN 1 PROMOTER - The present invention relates to a transgenic animal, which comprises in its genome a recombinant polynucleotide encoding one or more reporter proteins and a monocyte chemotactic protein-1 (MCP-1) promoter, wherein the one or more reporter proteins are expressed under the control of the MCP-1 promoter. A method for monitoring endogenous expression of MCP-1 in vivo is also provided, which is useful for identifying a regulator of the expression of MCP-1 or an anti-inflammatory agent. | 05-26-2011 |
| 20110081395 | ULTRA-NANOCRYSTALLINE DIAMOND AS A BIOMATERIAL FOR ENHANCING PROLIFERATION AND DIFFERENTIATION OF NEURAL STEM CELLS - Compositions for promoting growth and/or differentiation of a stem cell are disclosed. The composition comprises: a) a diamond film; b) a stem cell cultured on the diamond film; and c) a medium bathing the stem cell. The stem cell may be a mammalian neural stem cell and the diamond film may comprise a hydrogen-terminated or an oxygen-terminated surface. The hydrogen-terminated surface promotes proliferation and differentiation of a neural stem cell into neurons, and the oxygen-terminated surface promotes a neural stem cell to proliferate and differentiate into oligodendrocytes. | 04-07-2011 |
| 20110052711 | CONTROLLED RELEASE MULTIDRUG FORMULATIONS FOR SPINAL CORD INJURY - A controlled release multidrug formulation for improving locomotor recovery after spinal cord injury comprising: (a) a first composition comprising a first bioactive agent, encapsulated within a first polymeric particle; (b) a second composition comprising a second bioactive agent, encapsulated within a second polymeric particle, wherein the second polymeric particle is encapsulated within the first polymeric particle; and (c) a third composition comprising a third bioactive agent, encapsulated within either the first or the second polymeric particle, wherein the second composition is released subsequently to the release of the first composition, and wherein the first bioactive agent is a neurotrophic factor, the second bioactive agent is a collagen synthesis inhibitor, and the third bioactive agent is selected from the group consisting of cyclic AMP (cAMP), an adenylate cyclase activator and a Rho inhibitor. | 03-03-2011 |
| 20110052633 | MULTI-PHASE EMULSIONS BASED ON AMPHIPHILIC BLOCK COPOLYMERS - An composition comprises (a) a continuous aqueous phase; (b) an oily phase; and (c) an amphiphilic emulsifying system comprising a block copolymer having the formula (A)p-(B)q-(C)r, in which (B)q is a hydrophilic block and (C)r is a hydrophobic block; wherein p, q and r are integers with the proviso that: if p is 0, then A is other than hydroxyl or reactive functional groups and the block copolymer is a diblock copolymer; B and C are each individual repeating) units; if p is >1, then the block copolymer is a triblock copolymer, in which (A)p is a hydrophobic block; the hydrophobic blocks (A)p and (C)r are each homopolymers or heteropolymers; the repeating units A and C are the same or different; and wherein the ratio q/(p+r) is sufficient high so that the hydrophilic-lipophilic balance value of the block copolymer is >10. | 03-03-2011 |
| 20110038894 | Immunogenic Peptides of Tumor Associated Antigen L6 and Uses Thereof in Cancer Therapy - An immunopeptide containing a T cell epitope from the tumor associated antigen L6 (TAL6) and a nucleic acid encoding the immunopeptide. The immunopeptide and its encoding nucleic acid can be used as a component of an immune composition for enhancing immune response against cancer cells that express TAL6. | 02-17-2011 |
| 20110034808 | Dual-Curvature Phased Array High-Intensity Focused Ultrasound Transducer for Tumor Therapy - A transducer for use with a high intensity focused ultrasound medical system, said transducer comprises a plurality of transducer elements that are made from multi piezocomposite material; said plurality of transducer elements bonded together in turn with an adhesive and said transducer elements deployed along a geometric structure with two curvatures, and a plurality of electrodes arranged on said transducer for exciting said transducer elements in different phases to emit ultrasonic waves in response to an electrical signal applied to said electrodes to form or to be steered to a common focus center in a desired ablation area. | 02-10-2011 |
| 20110023136 | F1B-TMIR Plasmid Vector and Transgenic Mouse - A trifusion reporter plasmid is described that comprises a plasmid operably coupled to a mammalian FGF1B promoter that is operably coupled to a bioluminescence gene fused to a fluorescence gene fused to a nuclear medical imaging gene. The new reporter allows in vivo or ex vivo detection of gene expression in three different ways, in addition to traditional in vitro detection methods. Transgenic animals containing this new trifusion reporter and uses of same are described. | 01-27-2011 |
| 20110014220 | HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE - The present invention relates to a vaccine composition against the infection of human respiratory syncytial virus (RSV) comprising a replication-defective recombinant adenovirus carrying a nucleotide sequence encoding the F protein of RSV or fragment thereof. A method of preventing RSV infection-related diseases using the vaccine composition of the present invention is also provided. | 01-20-2011 |
| 20100322953 | Lipidated Tumor-Associated Antigens and Immunotherapeutic Compositions - Disclosed are polypeptides and fusion proteins. Also disclosed are related immunotherapeutic compositions and methods. | 12-23-2010 |
| 20100303849 | Lipidated Vaccine against Dengue Virus Infection - Disclosed are immunogenic composition, fusion proteins, and related methods for inducing immune response to dengue virus infection. | 12-02-2010 |
| 20100272747 | POLYVALENT CHIMERIC RUBELLA VIRUS-BASED VACCINES - A chimeric viral particle that comprises a RV fusion gene is disclosed. The RV fusion gene comprises a first nucleotide sequence encoding a RV that is devoid of RV E1 protein, and a second nucleotide sequence that linked in translation frame to the first nucleotide sequence and encodes a humoral immunogenic viral protein. The chimeric viral particle is free of RV E1 protein-encoding gene. A virus packaging cell that generates the chimeric viral particle comprising a RV fusion gene and an isolated expression vector comprising a RV fusion gene linked in translation frame to a promoter are also disclosed. | 10-28-2010 |
| 20100235927 | NON-HUMAN ANIMAL MODEL FOR LUNG CARCINOMA - A transgenic mouse expressing JSRV Env transgene that is operably linked to a surfactant protein C promoter (SPCp) is disclosed. The transgenic mouse is prone to developing a lung tumor and serves as an animal model for human lung carcinoma. | 09-16-2010 |
| 20100234431 | PYRROLIDINE COMPOUNDS - A compound of the following formula: | 09-16-2010 |
| 20100216773 | PHENANTHROINDOLIZIDINE ANALOGUES - Treatment of coronavirus infection with phenanthroindolizidine analogues. | 08-26-2010 |
| 20100172925 | HLA-A2-RESTRICTED T-CELL EPITOPES OF THE RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN AS PEPTIDE-BASED VACCINES - Respiratory syncytial virus (RSV) fusion protein-specific T-cell epitopes as peptide-based vaccines are disclosed. The isolated peptide contains a human HLA restricted CD8+ T-cell epitope that is specific to RSV F protein. The length of the peptide is no more than 9 or 10 amino acid residues. The peptide may be employed as an immunogen to stimulate cytotoxic T cells, indirectly activate helper T cells type 1, and cause release of cytokines from T cells. | 07-08-2010 |
| 20100166785 | ADJUVANTS - Disclosed are lipopeptides or lipoproteins, related compositions, and related methods. | 07-01-2010 |
| 20100150828 | RADIOACTIVE GOLD NANOPARTICLES AND METHODS OF MAKING AND USING THEM - Methods of preparing a composition comprising non-ionic, radioactive gold nanoparticles (R-GNPs) are disclosed. The method comprises: a) providing a solution comprising gold (Au-197) ions; and b) exposing the solution to neutron irradiation to generate a composition comprising non-ionic R-GNPs. Alternatively, the method comprises: a) providing a solution that comprises a composition comprising gold (Au-197) nanoparticles (GNPs); and b) exposing the GNP solution to neutron irradiation to generate a composition comprising non-ionic R-GNPs. Compositions that comprises non-ionic R-GNPs encapsulated within and/or anchored to MSNs, and methods of making the same are also disclosed. | 06-17-2010 |
| 20100120805 | Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors - Fused bicyclic or tricyclic compounds of formula (I): | 05-13-2010 |
| 20100113546 | Imidazol-4-one and Imidazole-4-thione Compounds - Imidazol-4-one or imidazole-4-thione compounds of formula (I): | 05-06-2010 |
| 20100081675 | FUSED MULTICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS - Fused multicyclic compounds of formula (I): | 04-01-2010 |
| 20100068240 | IMPLANTABLE NERVE REGENERATION CONDUIT - Implantable nerve regeneration conduits and methods of making the same are disclosed. The implantable nerve regeneration conduits mainly comprise a biodegradable polymer and a metal. Moreover, the conduits may also comprise one or more nerve regeneration enhancing elements, which comprise bioactive molecules or cells. The inner surface of the conduits may be micropatterned photolithographic processes to form microgrooves for facilitating cell alignment. | 03-18-2010 |
| 20100021957 | FUNCTIONALIZED QUANTUM DOTS AND METHODS FOR PREPARING THEM - A quantum dot (QD) conjugate comprises a QD and a ligand conjugated with the QD, in which the ligand has at least one thiol and at least one other functional group. The QD conjugate may further comprise a bioactive agent covalently coupled to the ligand to form a bioactive agent-tagged QD conjugate. A method for preparing a QD conjugate comprises the steps of: (1) providing a solution comprising a QD encapsulated within a dendrimer; (2) adding into the solution a ligand; and (3) allowing an exchange between the ligand and the dendrimer for the QD to obtain a ligand-QD conjugate, in which the ligand is covalently conjugated to the surface of the QD. The method may further comprise the step of coupling the ligand-QD conjugate to a bioactive agent to obtain a bioactive agent-tagged ligand-QD conjugate. | 01-28-2010 |
| 20100010059 | ANTICANCER ORAL FORMULATION - This invention relates to an oral formulation containing an effective amount of the compound of the following formula I: | 01-14-2010 |
| 20100003668 | Oligonucleotides and Use Thereof for Determining Deletion in HBV Pre-S Region - This invention provides combinations of novel oligonucleotides and their use in detecting a deletion(s) in the Pre-S region of HBV. Such a deletion(s) is associated with an increased risk of developing cirrhosis or hepatocellular carcinoma. | 01-07-2010 |
| 20100003257 | Diagnosis of nasopharyngeal carcinoma and suppression of nasopharyngeal carcinoma invasion - A diagnostic method for NPC based on the activation level of the Gα | 01-07-2010 |
| 20090312317 | COUMARIN COMPOUNDS AND THEIR USE FOR TREATING CANCER - Coumarin compounds of formula (I): | 12-17-2009 |
| 20090291133 | METHODS AND COMPOSTIONS FOR ENHANCING TRANSDERMAL DRUG DELIVERY - Methods and compositions for enhancing transdermal delivery of a bioactive agent. The method contains the step of applying to a skin tissue an effective amount of a composition comprising: (a) a drug vehicle; (b) a bioactive agent encapsulated within the drug vehicle; (c) a plurality of proteolytic enzyme molecules conjugated onto the surface of the drug vehicle; and (d) a pharmaceutically acceptable carrier, for a period of time effective to deliver the bioactive agent across the skin tissue at a desired dosage. | 11-26-2009 |
| 20090275596 | Treatment of Neurodegenerative Disorders with Thiourea Compounds - A method for treating a neurodegenerative disorder. The method includes administering to a subject in need thereof an effective amount of one or more thiourea compounds of formula (I) or (II): | 11-05-2009 |
| 20090275533 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS - Fused bicyclic pyrimidine compounds of formula (I): | 11-05-2009 |
| 20090274630 | RED BLOOD CELL-DERIVED VESICLES AS A NANOPARTICLE DRUG DELIVERY SYSTEM - Red blood cell-derived vesicles (RDV) as a nanoparticle drug delivery system. The RDV are smaller than one micrometer, capable of encapsulating and delivering an exogenous substance into cells. The substance may be at least one selected from the group consisting of fluorophores, nucleic acids, superparamagnetic compounds and therapeutic agents. The RDV are capable of delivering encapsulated substances into cells including stem cells. The delivered substance within the cell or stem cell may be traced or tracked using a suitable device either in vitro or in vivo. | 11-05-2009 |
| 20090239230 | Lung Cancer Diagnosis Based on Expression Levels of GIMAP Genes - Diagnosis of lung cancer based on the expression level(s) of one or more GTPase of Immunity-Associated Proteins (GIMAP) and method for identifying anti-lung cancer drug candidates based on their up-regulation of GIMAP activity. | 09-24-2009 |
| 20090221499 | Lipidating Sequences and Use thereof for Producing Lipidated Proteins in E. Coli - Production in | 09-03-2009 |
| 20090220985 | RAPID EFFICACY ASSESSMENT METHOD FOR LUNG CANCER THERAPY - The present invention discloses a method for rapid assessment of lung cancer therapy efficacy in a few days instead of weeks by conventional imaging methods. This method can also be used to detect relapse of the cancer and to improve the current TNM cancer staging method for more accurate prognosis. The rapid assessment of therapy efficacy is based on detecting circulating cancer cells in body fluid with high positive detection rate. The high positive detection rate is achieved by using qPCR amplification of multiple marker genes identified by in silico search of DNA sequence database. This invention also discloses a scoring method to calculate the cancer cell load based on qPCR results to correlate the amount of circulating cancer cells in lung cancer patients and predict the treatment outcomes. | 09-03-2009 |
| 20090196885 | Cancer Treatment - This invention relates to a method of treating cancer by administering to a subject in need thereof an effective amount of a mevalonate pathway inhibitor and an effective amount of an | 08-06-2009 |
| 20090176766 | IMIDAZOLIDINONE AND IMIDAZOLIDINETHIONE DERIVATIVES - Imidazolidinone and imidazolinethione compounds of formula (I): | 07-09-2009 |
| 20090176273 | Production of Lipidated Proteins In E. coli - Production of a lipidated protein in an | 07-09-2009 |
| 20090171185 | POSITIONING SYSTEM FOR THERMAL THERAPY - Systems and methods are provided for positioning a therapeutic device relative to a target displaced on a platform. A base member has a first track extending along a length of the platform for defining a first pathway for translating the therapeutic device relative to the target. A curved frame is slidably mounted on the base member through the first track. The curved frame has a second track along an interior wall of the curved frame for defining a second pathway for translating the therapeutic device relative to the target. A housing is disposed in the second track of the curved frame and configured to receive the therapeutic device. The housing is extendible at least along a radial direction of the curved frame for defining a third pathway for translating the therapeutic device relative to the target. Applications of the systems and methods may include image-guided thermal therapy. | 07-02-2009 |
| 20090117123 | IMMUNOPEPTIDES OF HPV E6 AND E7 PROTEINS - An immunopeptide containing a cytotoxic T lymphocyte epitope derived from HPV E6 or HPV E7 protein. The immunopeptide can be used as a component of a vaccine for enhancing immune responses against HPV or treating HPV-associated diseases. Also within the scope of this invention are a nucleic acid encoding the immunopeptide and an antibody specific to the CTL epitope. | 05-07-2009 |
| 20090112132 | GENERATING GATING SIGNALS FOR THERMAL THERAPY - A method of inducing thermal effect at a moving target includes receiving a first data characterizing a repeated motion of the moving target; processing the first data to determine a treatment plan, including determining a plan for directing a signal at the moving target; and controlling the signal directed at the moving target according to the treatment plan to induce a thermal effect. | 04-30-2009 |
| 20090082406 | Cancer Therapy - This invention relates to a method of regulating the cell cycle and treating cancer with a peroxisome proliferator-activated receptor γ agonist and a mevalonate pathway inhibitor or a mevalonate antagonist. | 03-26-2009 |
| 20090042864 | PYRAZOLE COMPOUNDS -
This invention relates to pyrazole compounds of formula (I) shown below:
| 02-12-2009 |
| 20090029969 | Thiophene Compounds -
This invention relates to thiophene compounds of formula (I) shown below:
| 01-29-2009 |
| 20090022735 | Receptor Binding Polypeptides - Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed. | 01-22-2009 |
| 20090004258 | Drug Release from Thermosensitive Liposomes by Applying an Alternative Magnetic Field - Thermosensitive liposomes encapsulating paramagnetic iron oxide nanoparticles are used as a drug controlled release system. Paramagnetic iron oxide nanoparticles are used to generate heat by applying alternative magnetic field to cause leakage of drugs in the liposomes. | 01-01-2009 |
| 20080306090 | THIOUREA DERIVATIVES - Thiourea compounds of the following formula: | 12-11-2008 |
| 20080275331 | DETECTING TEMPERATURE AND PROTEIN DENATURATION DURING THERMAL THERAPY - In one aspect, in general, a method is provided for detecting temperature and protein denaturation of a tissue during thermal therapy. The method includes generating a plurality of MR pulse sequences that include a first group of pulse sequences and a second group of pulse sequences, and receiving a plurality of response signals that include a first and second group of response signals in response to the first and second groups of pulse sequences, respectively. A first information associated with a degree of protein denaturation of the tissue is determined based on the first and second groups of response signals. A second information associated with a temperature of the tissue is determined based on at least some of the plurality of response signals. | 11-06-2008 |
| 20080255211 | Oxadiazole Compounds - A compound of formula (I): | 10-16-2008 |
| 20080255189 | HEPATITIS C VIRUS INHIBITORS - A compound of the following formula: | 10-16-2008 |
| 20080242701 | Novel Compounds And Methods Of Use Thereof - This invention relates to treating cancer or an angiogenesis-related disease using a compound of formula 1: | 10-02-2008 |
| 20080202208 | NANO-PARTICLE CONTAINING APPARATUS, NANO-PARTICLE DETECTION SYSTEM AND METHOD THEREOF - A nano-particle containing apparatus, a nano-particle detection system and a method are disclosed. The nano-particle containing apparatus includes a casing, an air extracting device, a pressure device and a measuring instrument. The casing has a containing space for disposing a plurality of nano-particles. An internal wall surface of the casing has active self-cleaning function. The pressure control device controls the pressure status of the containing space. The active self-clean function is that nano-particles adhered to the internal surface wall are removed into the containing space. The nano-particles then are pumped by the air extracting device from the containing space. The measuring instrument then detects the status of an object affected by the nano-particles after the object is delivered into the containing space. | 08-28-2008 |
| 20080200806 | Medical Treatment Using An Ultrasound Phased Array - A medical system and method for treating a disorder of a subject by thermal ablation, e.g., focused ultrasound thermal ablation, are provided. The method includes obtaining medical images that include at least one image of subject's chest and ribs to reconstruct a three-dimensional chest-rib distribution; and applying ultrasound waves on a target point beyond the subject's ribs by selectively activating one or more elements of an ultrasound phased array to avoid ultrasonic energy absorption or reflection by an intervening rib based on a calculation of a relationship between the three-dimensional chest-rib distribution and an acoustic emission direction. | 08-21-2008 |
